Purpose: Anaplastic thyroid carcinoma (ATC) is a rare, highly aggressive form of thyroid cancer (TC) characterized by an aggressive behavior and poor prognosis, resulting in patients’ death within a year. Standard treatments, such as chemo and radiotherapy, as well as tyrosine kinase inhibitors, are ineffective for ATC treatment. Cancer immunotherapy is one of the most promising research area in oncology. The PD-1/PD-L1 axis is of particular interest, in light of promising data showing a restoration of host immunity against tumours, with the prospect of long-lasting remissions. Methods: In this study, we evaluated PD-L1 expression in a large series of TCs (20 cases) showing a progressive dedifferentiation of the thyroid tumour from well differentiated TC to ATC, employing two different antibodies [R&D Systems and VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody]. We also tested the anti PD-L1 mAb in an in vivo animal model. Results: We found that approximately 70-90% of ATC cases were positive for PD-L1 whereas normal thyroid and differentiated TC were negative. Moreover, all analyzed cases presented immunopositive staining in the endothelium of vessels within or in close proximity to the tumour, while normal thyroid vessels were negative. PD-L1 mAb was also effective in inhibiting ATC growth in an in vivo model. Conclusions: These data suggest that immunotherapy may be a promising treatment specific for ATC suggesting the need to start with clinical TRIALs.

Cantara, S., Bertelli, E., Occhini, R., Regoli, M., Brilli, L., Pacini, F., et al. (2019). Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. ENDOCRINE, 64(1), 122-129 [10.1007/s12020-019-01865-5].

Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer

Cantara, Silvia
Writing – Original Draft Preparation
;
Bertelli, Eugenio
Writing – Original Draft Preparation
;
Occhini, Rossella
Conceptualization
;
Regoli, Marì
Investigation
;
Pacini, Furio
Writing – Review & Editing
;
Castagna, Maria Grazia
Investigation
;
Toti, Paolo
Investigation
2019-01-01

Abstract

Purpose: Anaplastic thyroid carcinoma (ATC) is a rare, highly aggressive form of thyroid cancer (TC) characterized by an aggressive behavior and poor prognosis, resulting in patients’ death within a year. Standard treatments, such as chemo and radiotherapy, as well as tyrosine kinase inhibitors, are ineffective for ATC treatment. Cancer immunotherapy is one of the most promising research area in oncology. The PD-1/PD-L1 axis is of particular interest, in light of promising data showing a restoration of host immunity against tumours, with the prospect of long-lasting remissions. Methods: In this study, we evaluated PD-L1 expression in a large series of TCs (20 cases) showing a progressive dedifferentiation of the thyroid tumour from well differentiated TC to ATC, employing two different antibodies [R&D Systems and VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody]. We also tested the anti PD-L1 mAb in an in vivo animal model. Results: We found that approximately 70-90% of ATC cases were positive for PD-L1 whereas normal thyroid and differentiated TC were negative. Moreover, all analyzed cases presented immunopositive staining in the endothelium of vessels within or in close proximity to the tumour, while normal thyroid vessels were negative. PD-L1 mAb was also effective in inhibiting ATC growth in an in vivo model. Conclusions: These data suggest that immunotherapy may be a promising treatment specific for ATC suggesting the need to start with clinical TRIALs.
Cantara, S., Bertelli, E., Occhini, R., Regoli, M., Brilli, L., Pacini, F., et al. (2019). Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. ENDOCRINE, 64(1), 122-129 [10.1007/s12020-019-01865-5].
File in questo prodotto:
File Dimensione Formato  
Cantara2019_Article_BlockadeOfTheProgrammedDeathLi.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 2.34 MB
Formato Adobe PDF
2.34 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Cantara et al revised text final post-print version Bertelli.pdf

accesso aperto

Descrizione: his version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s12020-019-01865-5
Tipologia: Post-print
Licenza: PUBBLICO - Pubblico con Copyright
Dimensione 2.53 MB
Formato Adobe PDF
2.53 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1068627